Under CSF-1R inhibition, the tumor microenvironment drives treatment resistance via stimulation of the PI3K signaling caused by tumor cell IGF-1 receptor (IGF-1R) and macrophage-derived insulin-like growth factor-1 (IGF-1). The gene discussed is IGF1; the disease is neoplasm.